U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT03835715) titled 'Study With Vortioxetine on Emotional Functioning in Patients With Depression' on Feb. 7.
Brief Summary: The study will evaluate effectiveness of flexible dose vortioxetine 10-20 mg/day on emotional functioning in patients with MDD with an inadequate response to SSRIs/SNRIs.
Study Type: Interventional
Condition: Major Depressive Disorder
Intervention: Drug: Vortioxetine
Flexible doses (10-20 mg) of vortioxetine; 10 mg during the first week which may be increased up to 20 mg week 2-8
Other Name: Brintellix (R)
Recruitment Status: Recruiting
Sponsor: H. Lundbeck A/S
Information provided by (Responsible Party): H. Lundbeck A/S
...